These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23151189)

  • 21. Histamine H4 receptor ligands and their potential therapeutic applications: an update.
    Kiss R; Keserű GM
    Expert Opin Ther Pat; 2012 Mar; 22(3):205-21. PubMed ID: 22385042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostanoid-induced relaxation of precontracted cat ciliary muscle is mediated by EP2 and DP receptors.
    Chen J; Woodward DF
    Invest Ophthalmol Vis Sci; 1992 Oct; 33(11):3195-201. PubMed ID: 1328113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. D-type prostanoid receptor enhances the signaling of chemoattractant receptor-homologous molecule expressed on T(H)2 cells.
    Sedej M; Schröder R; Bell K; Platzer W; Vukoja A; Kostenis E; Heinemann A; Waldhoer M
    J Allergy Clin Immunol; 2012 Feb; 129(2):492-500, 500.e1-9. PubMed ID: 21930295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective cannabinoid receptor 2 modulators: a patent review 2009--present.
    Riether D
    Expert Opin Ther Pat; 2012 May; 22(5):495-510. PubMed ID: 22537079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The potential of selected prostanoid receptors as targets in a new therapeutic strategy for allergy and immune diseases.
    Kabashima K; Tokura Y
    Curr Drug Saf; 2007 Sep; 2(3):186-92. PubMed ID: 18690966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
    Abramovitz M; Adam M; Boie Y; Carrière M; Denis D; Godbout C; Lamontagne S; Rochette C; Sawyer N; Tremblay NM; Belley M; Gallant M; Dufresne C; Gareau Y; Ruel R; Juteau H; Labelle M; Ouimet N; Metters KM
    Biochim Biophys Acta; 2000 Jan; 1483(2):285-93. PubMed ID: 10634944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Piglet saphenous vein contains multiple relaxatory prostanoid receptors: evidence for EP4, EP2, DP and IP receptor subtypes.
    Wilson RJ; Giles H
    Br J Pharmacol; 2005 Feb; 144(3):405-15. PubMed ID: 15655509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Replacement of the carboxylic acid group of prostaglandin f(2alpha) with a hydroxyl or methoxy substituent provides biologically unique compounds.
    Woodward DF; Krauss AH; Chen J; Gil DW; Kedzie KM; Protzman CE; Shi L; Chen R; Krauss HA; Bogardus A; Dinh HT; Wheeler LA; Andrews SW; Burk RM; Gac T; Roof MB; Garst ME; Kaplan LJ; Sachs G; Pierce KL; Regan JW; Ross RA; Chan MF
    Br J Pharmacol; 2000 Aug; 130(8):1933-43. PubMed ID: 10952685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. E-ring isoprostane augments cholinergic neurotransmission in bovine trachealis via FP prostanoid receptors.
    Paredes C; Tazzeo T; Janssen LJ
    Am J Respir Cell Mol Biol; 2007 Dec; 37(6):739-47. PubMed ID: 17630320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostanoid-induced blood-aqueous barrier breakdown in rabbits involves the EP2 receptor subtype.
    Protzman CE; Woodward DF
    Invest Ophthalmol Vis Sci; 1990 Nov; 31(11):2463-6. PubMed ID: 2173691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel GABA(B) receptor positive modulators: a patent survey.
    Froestl W
    Expert Opin Ther Pat; 2010 Aug; 20(8):1007-17. PubMed ID: 20645682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DP(2) receptor antagonists in development.
    Norman P
    Expert Opin Investig Drugs; 2010 Aug; 19(8):947-61. PubMed ID: 20615077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostanoid receptors in the human vascular wall.
    Norel X
    ScientificWorldJournal; 2007 Sep; 7():1359-74. PubMed ID: 17767355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostaglandins in the kidney: developments since Y2K.
    Nasrallah R; Clark J; Hébert RL
    Clin Sci (Lond); 2007 Oct; 113(7):297-311. PubMed ID: 17760567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation.
    Meja KK; Barnes PJ; Giembycz MA
    Br J Pharmacol; 1997 Sep; 122(1):149-57. PubMed ID: 9298541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging roles of DP and CRTH2 in allergic inflammation.
    Kostenis E; Ulven T
    Trends Mol Med; 2006 Apr; 12(4):148-58. PubMed ID: 16545607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostaglandins; their biological and pharmacological role.
    Vapaatalo H; Parantainen J
    Med Biol; 1978 Aug; 56(4):163-83. PubMed ID: 212650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TRP channels as therapeutic targets in airway disorders: a patent review.
    Preti D; Szallasi A; Patacchini R
    Expert Opin Ther Pat; 2012 Jun; 22(6):663-95. PubMed ID: 22667456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostanoids as regulators of innate and adaptive immunity.
    Hirata T; Narumiya S
    Adv Immunol; 2012; 116():143-74. PubMed ID: 23063076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostanoid TP receptor-mediated impairment of cyclic AMP-dependent vasorelaxation is reversed by phosphodiesterase inhibitors.
    Liu CQ; Wong SL; Leung FP; Tian XY; Lau CW; Lu L; Yao X; Chen ZY; Yao T; Huang Y
    Eur J Pharmacol; 2010 Apr; 632(1-3):45-51. PubMed ID: 20096281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.